Please assess the completion status of the following clinical trial:

Trial Title: Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed acute lymphoblastic leukemia (ALL)~  * Definitive evidence of BCR-ABL fusion (Philadelphia chromosome positive \[PH+\]) from an approved Children's Oncology Group (COG) cytogenetics laboratory~* Meets one of the following criteria:~  * Concurrent enrollment on Clusters of Orthologous Groups (COG)-AALL03B1 (or a successor trial) AND COG-AALL0232, COG-AALL0331, COG-AALL0434 or other front-line COG ALL clinical trial~ * Concurrent enrollment on COG-AALL03B1 (or a successor trial) AND scheduled to receive a 3 or 4-drug standard induction regimen~ * Concurrent enrollment on a Dana-Farber Cancer Institute (DFCI) Childhood ALL Consortium trial (or scheduled to be treated as per a DFCI Childhood ALL Consortium induction regimen)~* All patients must have definitive evidence of BCR-ABL fusion from an approved COG cytogenetics laboratory; patients may NOT have received Day 15 of Induction chemotherapy (or day 18 vincristine if enrolled on a DFCI Childhood ALL Consortium trial) prior to enrollment on AALL0622~* Patients must have a performance status of 0, 1 or 2 at completion of two weeks of Induction; use Karnofsky for patients \> 16 years of age and Lansky for patients =\< 16 years of age~* Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70mL/min/1.73 m\^2 or maximum serum creatinine based on age and gender as follows:~  * 0.4 mg/dL (for patients 1 to 5 months of age)~ * 0.5 mg/dL (for patients 6 to 11 months of age)~ * 0.6 mg/dL (for patients 1 year of age)~ * 0.8 mg/dL (for patients 2 to 5 years of age)~ * 1.0 mg/dL (for patients 6 to 9 years of age)~ * 1.2 mg/dL (for patients 10 to 12 years of age)~ * 1.5 mg/dL (males) or 1.4 mg/dL (females) (for patients 13 to 15 years of age)~ * 1.7 mg/dL (males) or 1.4 mg/dL (females) (for patients \>= 16 years of age)~* Total bilirubin =\< 1.5 times upper limit of normal (ULN) for age~* Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) \< 2.5 times ULN for age~* Shortening fraction \>= 27% by echocardiogram or ejection fraction \>= 50% by gated radionuclide study~* No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry \> 94% at sea level if there is clinical indication for determination~* Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled; however, drugs that induce CYP3A4/5 (carbamazepine, oxcarbazepine, phenytoin, primidone, phenobarbital) should be avoided~* Patients will start AALL0622 therapy on day 15 of induction therapy (or day 18 if enrolled on a DFCI Childhood ALL Consortium trial); patients must have received the first 2 weeks of Induction therapy~Exclusion Criteria:~* Females of childbearing potential must have a negative pregnancy test; patients of childbearing potential must agree to use an effective birth control method~* Female patients who are lactating must agree to stop breast-feeding~* Patients with Down syndrome~* Patients with any clinically significant cardiovascular disease including the following:~  * Myocardial infarction or ventricular tachyarrhythmia within 6 months~ * Ejection fraction less than institutional normal~ * Major conduction abnormality (unless a cardiac pacemaker is present)

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (enzyme inhibitor therapy and chemotherapy) (Type: EXPERIMENTAL): See Detailed Description

Based on this trial design, predict the completion outcome and termination type (if applicable).